TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05319314: LYL273 for Patients With Relapsed or Refractory mCRC

Sponsor: Lyell Immunopharma, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 155 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05319314 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05319314 Rescue Dossier →